Dr. Rahul Purwar is a professor at Department of Biosciences and Bioengineering at IIT Bombay. He
holds a Ph.D. in Molecular Medicine from Hannover Medical School, Germany. Dr. Rahul’s
professional journey spans various prestigious institutions and roles. He started his post-doctoral
fellowship at Harvard Medical School, Boston, USA. After his fellowship, he joined ImmunoGen,
Inc. (Boston, USA), as a scientist before returning to India as a faculty member at IIT Bombay.
His lab at IIT Bombay developed indigenous technology platform for CD19 CAR-T cell therapy, a
type of gene therapy. Based on his research at IIT Bombay, Dr Purwar founded ImmunoACT in 2018,
first cell & gene therapy company in India. Upon successful multiple clinical trials, ImmunoACT
received market authorization of the country’s first CAR-T cell therapy, and Honorable President of
India dedicated CAR-T cell therapy to the nation on April 4th, 2024. This is the first of many planned
milestones in democratizing access to advanced cell & gene therapies in India.
Dr. Purwar’s research work is well-recognized in the scientific community, with numerous
publications to his credit in esteemed journals. His contributions to the field of Biosciences &
Bioengineering are commendable and his work continues to inspire many in the scientific community.